Corporate Profile
Sensei is a clinical-stage immunotherapy company committed to the discovery and development of next-generation therapies for the treatment of cancer. Its proprietary ImmunoPhage platform, leveraging the self-adjuvanted and highly immunogenic properties of engineered bacteriophage, allows Sensei to develop novel therapeutics that target key mechanisms of checkpoint resistance to induce a robust, focused and coordinated immune response.
Sensei is developing a library of ImmunoPhage targeting multiple tumor-associated antigens utilizing its proprietary platform and GMP manufacturing facility to treat patients using a personalized, yet off the shelf cocktail approach.
Sensei’s pipeline includes its lead product candidate, SNS-301, which is currently being evaluated in combination with the PD-1 inhibitor, pembrolizumab, for the treatment of squamous cell carcinoma of the head and neck.
Additional preclinical programs include SNS-401 for the treatment of Merkel cell carcinoma and a human monoclonal antibody program targeting the immune checkpoint VISTA, or V-set immunoglobulin domain suppressor of T cell activation.
Sensei is developing a library of ImmunoPhage targeting multiple tumor-associated antigens utilizing its proprietary platform and GMP manufacturing facility to treat patients using a personalized, yet off the shelf cocktail approach.
Sensei’s pipeline includes its lead product candidate, SNS-301, which is currently being evaluated in combination with the PD-1 inhibitor, pembrolizumab, for the treatment of squamous cell carcinoma of the head and neck.
Additional preclinical programs include SNS-401 for the treatment of Merkel cell carcinoma and a human monoclonal antibody program targeting the immune checkpoint VISTA, or V-set immunoglobulin domain suppressor of T cell activation.
Day High
Day Low
52 Week High
52 Week Low
Volume
Data Provided by Refinitiv. Minimum 15 minutes delayed.